Glenmark Pharmaceuticals shines on reporting 9-fold jump in Q1 consolidated net profit
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Glenmark Pharmaceuticals is currently trading at Rs. 1560.95, up by 69.95 points or 4.69% from its previous closing of Rs. 1491.00 on the BSE.
The scrip opened at Rs. 1518.70 and has touched a high and low of Rs. 1576.65 and Rs. 1427.35 respectively. So far 145427 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1576.65 on 16-Aug-2024 and a 52 week low of Rs. 702.05 on 12-Nov-2023.
Last one week high and low of the scrip stood at Rs. 1576.65 and Rs. 1427.35 respectively. The current market cap of the company is Rs. 44042.52 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 34.94% and 18.41% respectively.
Glenmark Pharmaceuticals has reported 67.02% rise in net profit at Rs 453.73 crore for the first quarter ended June 30, 2024 (Q1FY25) as compared to Rs 271.66 crore for the same quarter in the previous year. Total income of the company increased by 8.73% at Rs 2385.19 crore for Q1FY25 as compared to Rs 2193.75 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 9- fold jump in its net profit at Rs 340.24 crore for the quarter ended June 30, 2024 as compared to Rs 37.68 crore for the same quarter in the previous year. Total income of the company increased by 7.20% at Rs 3275.68 crore for Q1FY25 as compared to Rs 3055.79 crore for the corresponding quarter previous year.
.jpg)
